Monte Rosa Therapeutics carries roughly 55% theoretical upside to analyst consensus with meaningful institutional interest, but a quality score of 1.4, free cash flow burning at 180% of revenue, and two consecutive earnings misses make this an unsuitable position at minimum quality standards — the wide upside reflects pipeline optionality, not current business strength.
Thesis pillars
- Analyst Upside Pipeline Optionality↑Improving
- Cash Burn Quality Floor Breach→Stable
- Recent Earnings Miss Trend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 17, 2026
Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.85: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Below long-term trend.
Monte Rosa Therapeutics is a clinical-stage biotech developing molecular glue degraders (MGDs) using its proprietary QuEEN discovery engine and a library of more than 75,000 MGD compounds. Its clinical pipeline includes MRT-6160 (VAV1, licensed to Novartis), MRT-8102 (NEK7, for... Read more
Sell if holding. Engine safety override at $10.85: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 56. Score 4.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: speculative.
About Monte Rosa Therapeutics, Inc.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics has three molecular glue degraders (MGDs) in clinical development: MRT-6160, a VAV1-directed MGD licensed to Novartis for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for cardiovascular and inflammatory disease; and MRT-2359, a GSPT1-directed MGD for metastatic castration-resistant prostate cancer. The clinical-stage company has never generated product revenue, reporting a $38.6 million net loss in 2025 and holding $382.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025, funded in part by a $120.0 million upfront payment from a September 2025 Novartis collaboration.
As a pre-revenue biotech, Monte Rosa earns milestone and royalty income by licensing MGD programs to larger partners rather than commercializing drugs itself: Novartis paid $150 million upfront for global rights to MRT-6160 in October 2024, plus up to $2.1 billion in potential milestones and a 30% U.S. profit-and-loss share from Phase 3 onward, and paid a further $120.0 million upfront in September 2025 for an immunology and inflammation program plus options on two more preclinical programs. Roche separately paid $50 million upfront in October 2023 for rights to oncology and neuroscience targets discovered using Monte Rosa's QuEEN AI/ML platform, with potential milestones exceeding $2 billion. Monte Rosa retains full ownership of MRT-8102 and MRT-2359, which it plans to advance itself through Phase 2 studies, including GFORCE-2 (ASCVD), GFORCE-3 (gout), and GFORCE-4 (hidradenitis suppurativa) for MRT-8102, and a Phase 2 AR-mutation study for MRT-2359, both expected to start in 2026.
Show full overview
Monte Rosa's near-term trajectory now runs largely through partners rather than its own commercial execution: Novartis controls all further clinical development and commercialization of MRT-6160, and the 10-K states Monte Rosa's business is dependent on the success of its lead programs and any candidates it advances into the clinic. MRT-8102's Phase 1 GFORCE-1 data showed an 85% reduction in CRP after four weeks in elevated cardiovascular-risk patients, and results from the expanded multi-dose cohort are expected in the second half of 2026 -- a readout that will shape whether the wholly-owned NEK7 program can support a Phase 2 franchise across ASCVD, gout, and hidradenitis suppurativa without additional licensing.
See also: Healthcare · Biotechnology
From Monte Rosa Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Monte Rosa Therapeutics, Inc.
Latest news
- NEWS Monte Rosa Therapeutics Announces Milestone Achievement for MRT-6160 Clinical Study — fiscal.ai Oct 28, 2026 positive
- NEWS Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In — benzinga Oct 28, 2026 positive
- NEWS Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In Peop — benzinga Oct 28, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target — benzinga Oct 5, 2026 positive
- NEWS Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease — benzinga Oct 1, 2026 positive
Generated 2026-10-29T11:14:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineMRT-2359, MRT-6160, and MRT-8102 lead programs10-K Item 1A: 'Our business is dependent on the success of our lead programs, and any other product candidates that we advance into the clinic. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.85: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 56. Prior stop was $10.09. Score 4.8/10, moderate confidence.
Analyst target: $23.38 (+115.5% upside). Prior stop was $10.09. Stop-loss: $10.09.
Quality below floor (1.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 6.0), Material insider selling (6 sells, 4.87% of cap).
Monte Rosa Therapeutics, Inc. trades at a P/E of N/A (forward -5.9). TrendMatrix value score: 5.4/10. Verdict: Sell.
15 analysts cover GLUE with a consensus score of 4.3/5. Average price target: $27.
What does Monte Rosa Therapeutics, Inc. do?Monte Rosa Therapeutics is a clinical-stage biotech developing molecular glue degraders (MGDs) using its proprietary...
Monte Rosa Therapeutics is a clinical-stage biotech developing molecular glue degraders (MGDs) using its proprietary QuEEN discovery engine and a library of more than 75,000 MGD compounds. Its clinical pipeline includes MRT-6160 (VAV1, licensed to Novartis), MRT-8102 (NEK7, for cardiovascular and inflammatory disease), and MRT-2359 (GSPT1, for prostate cancer), alongside a separate Roche oncology/neuroscience collaboration. The company has never generated product revenue, reporting a $38.6 million net loss in 2025 against $382.1 million in cash and marketable securities as of December 31, 2025